KR20120032530A - 페미로라스트의 신규한 결정형 - Google Patents

페미로라스트의 신규한 결정형 Download PDF

Info

Publication number
KR20120032530A
KR20120032530A KR1020127001227A KR20127001227A KR20120032530A KR 20120032530 A KR20120032530 A KR 20120032530A KR 1020127001227 A KR1020127001227 A KR 1020127001227A KR 20127001227 A KR20127001227 A KR 20127001227A KR 20120032530 A KR20120032530 A KR 20120032530A
Authority
KR
South Korea
Prior art keywords
disease
compound
sodium
femirolast
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127001227A
Other languages
English (en)
Korean (ko)
Inventor
아네트 펄버그
마틴 비에르텔하우스
울리카 로젠스트롬
카롤 호르바트
Original Assignee
카르도스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카르도스 아베 filed Critical 카르도스 아베
Publication of KR20120032530A publication Critical patent/KR20120032530A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
KR1020127001227A 2009-06-16 2010-06-15 페미로라스트의 신규한 결정형 Ceased KR20120032530A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16
US61/187,355 2009-06-16
US61/187,348 2009-06-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012036A Division KR20170049645A (ko) 2009-06-16 2010-06-15 페미로라스트의 신규한 결정형

Publications (1)

Publication Number Publication Date
KR20120032530A true KR20120032530A (ko) 2012-04-05

Family

ID=43264726

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127001227A Ceased KR20120032530A (ko) 2009-06-16 2010-06-15 페미로라스트의 신규한 결정형
KR1020177012036A Ceased KR20170049645A (ko) 2009-06-16 2010-06-15 페미로라스트의 신규한 결정형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177012036A Ceased KR20170049645A (ko) 2009-06-16 2010-06-15 페미로라스트의 신규한 결정형

Country Status (31)

Country Link
US (3) US20120157415A1 (https=)
EP (2) EP2443120B1 (https=)
JP (2) JP5722317B2 (https=)
KR (2) KR20120032530A (https=)
CN (1) CN102596202B (https=)
AR (1) AR077915A1 (https=)
AU (1) AU2010261540B2 (https=)
BR (1) BRPI1015559A2 (https=)
CA (1) CA2765408A1 (https=)
CY (1) CY1118413T1 (https=)
DK (1) DK2443120T3 (https=)
EA (1) EA025865B1 (https=)
ES (1) ES2613059T3 (https=)
HR (1) HRP20170023T1 (https=)
HU (1) HUE032978T2 (https=)
IL (1) IL216670A (https=)
LT (1) LT2443120T (https=)
ME (1) ME02685B (https=)
MX (1) MX2011013676A (https=)
NZ (1) NZ596747A (https=)
PL (1) PL2443120T3 (https=)
PT (1) PT2443120T (https=)
RS (1) RS55558B1 (https=)
SA (1) SA114350792B1 (https=)
SG (1) SG176295A1 (https=)
SI (1) SI2443120T1 (https=)
SM (2) SMT201700085T1 (https=)
TW (1) TWI504599B (https=)
UY (1) UY32711A (https=)
WO (2) WO2010146341A2 (https=)
ZA (1) ZA201109045B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329813A1 (en) * 2009-11-13 2012-12-27 Cardoz Ab Pemirolast for the Treatment of Systemic Low Grade Inflammation
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
BR112019006429A2 (pt) * 2016-10-03 2019-06-25 Brivention Pharmaceutical Shanghai Inc composição compreendendo combinação de análogo de trh com ácido arúndico, e sal farmaceuticamente aceitável de ácido arúndico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド［１，２―ａ］ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
BRPI0615775B1 (pt) 2005-09-16 2021-08-10 Daiichi Sankyo Company, Limited Processos para a produção de compostos derivados de diamida oticamente ativos
NZ577467A (en) * 2006-12-18 2012-04-27 Cardoz Ab Combination of pemirolast and a statin for use in the treatment of inflammatory disorders
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
US9006431B2 (en) 2015-04-14
AU2010261540A1 (en) 2012-01-19
EA201200017A1 (ru) 2013-10-30
KR20170049645A (ko) 2017-05-10
HRP20170023T1 (hr) 2017-03-10
JP2015120750A (ja) 2015-07-02
IL216670A0 (en) 2012-02-29
CN102596202B (zh) 2015-01-21
SMT201700085B (it) 2017-03-08
EP2443120A2 (en) 2012-04-25
WO2010146348A9 (en) 2012-05-03
CY1118413T1 (el) 2017-06-28
ME02685B (me) 2017-06-20
SA114350792B1 (ar) 2015-11-10
JP2012530118A (ja) 2012-11-29
PL2443120T3 (pl) 2017-04-28
SI2443120T1 (sl) 2017-04-26
EA025865B1 (ru) 2017-02-28
RS55558B1 (sr) 2017-05-31
WO2010146341A3 (en) 2011-03-03
WO2010146341A2 (en) 2010-12-23
DK2443120T3 (en) 2017-01-09
JP5722317B2 (ja) 2015-05-20
US20120157415A1 (en) 2012-06-21
TW201100422A (en) 2011-01-01
NZ596747A (en) 2014-01-31
HUE032978T2 (hu) 2017-11-28
US20170202839A1 (en) 2017-07-20
UY32711A (es) 2011-01-31
CN102596202A (zh) 2012-07-18
SMT201700085T1 (it) 2017-03-08
SG176295A1 (en) 2012-01-30
WO2010146348A3 (en) 2011-03-03
EP2443120B1 (en) 2016-11-02
EP3141549A1 (en) 2017-03-15
BRPI1015559A2 (pt) 2016-04-26
AR077915A1 (es) 2011-10-05
MX2011013676A (es) 2012-02-08
US20140329839A1 (en) 2014-11-06
TWI504599B (zh) 2015-10-21
AU2010261540A2 (en) 2012-01-19
LT2443120T (lt) 2017-02-10
AU2010261540B2 (en) 2016-04-14
ES2613059T3 (es) 2017-05-22
CA2765408A1 (en) 2010-12-23
PT2443120T (pt) 2017-02-08
WO2010146348A2 (en) 2010-12-23
IL216670A (en) 2017-02-28
ZA201109045B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
US20170202839A1 (en) Crystalline Form of Pemirolast
KR101549318B1 (ko) 안지오텐신 수용체 길항제 및 ｎｅｐ 억제제의 제약 조합물
KR101598482B1 (ko) 도파민-베타-히드록실라아제의 저해제인 1,3-디히드로이미다졸-2-티온 유도체
TWI876902B (zh) 經四氫哌喃(thp)取代之雙環嘧啶二酮化合物
US20160250217A1 (en) Crystalline form of pemirolast
HK1238628A1 (en) Crystalline form of pemirolast for use in the treatment of inflammations
HK1169385B (en) Crystalline form of pemirolast
HK1169385A (en) Crystalline form of pemirolast
JP7082107B2 (ja) アミド誘導体
TW201028390A (en) Flavononol renin inhibitor compounds and methods of use thereof
JPWO2018066646A1 (ja) 尿素誘導体
RU2459809C2 (ru) Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2023208103A1 (zh) 可用于痛风的化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150615

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160520

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160520

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170502